Physiomics PLC Publication of article in Frontiers in Oncology
09 May 2023 - 4:00PM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
09 May 2023
9 May 2023
Physiomics plc
("Physiomics" or "the Company")
Publication of article in Frontiers in Oncology
Physiomics plc (AIM: PYC), a leading mathematical modelling
company supporting oncology drug development and personalised
medicine solutions, is pleased to announce the publication of an
original article "Should personalised dosing have a role in cancer
treatment?" in a special edition of the journal "Frontiers in
Oncology" focused on the FDA's Project Optimus. The full article
can be accessed via the following link:
https://www.frontiersin.org/articles/10.3389/fonc.2023.1154493/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Oncology&id=1154493.
Project Optimus has relevance to Physiomics both in its core
consulting business and its personalised oncology initiatives. In
core consulting, Project Optimus encourages and some would say even
mandates biotech and pharma companies to fully utilise all
available non-clinical and clinical data to make informed decisions
about clinical trial design and biologically effective dose. The
Company believes that there is an increasing expectation that
companies meeting with the FDA should have utilised mathematical
modelling in support of clinical trial design and dosing decision
making. The Company has first hand experience of this through the
translational modelling work it has completed for multiple small
and medium sized clients in recent years.
Looking beyond drug development, the Company sees a clear
implication of Project Optimus on dosing of approved drugs in
cancer. The vast majority of cancer drugs are still approved on a
"one size fits all" basis with, at most, adjustments in dosing
being made to account for body weight or surface area of individual
patients. The Company believes that the future direction of cancer
drug dosing will take into account its effect in each individual
and we believe that our personalised dosing tool is a clear step
towards achieving that goal.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling
techniques with cancer biology expertise, to help biotech and
pharma companies streamline their drug development journeys.
Our approach is to derive insight from all relevant data in
order to de-risk decision making and optimise design of
pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour
technology, the Physiomics team has informed the development of
over 100 projects, over 50 targets and 75 drugs. Clients include
Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUWUNROUUVRAR
(END) Dow Jones Newswires
May 09, 2023 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024